WO1993012779A1 - Compositions containing histamine-h2-receptor antagonists at low dosage - Google Patents
Compositions containing histamine-h2-receptor antagonists at low dosage Download PDFInfo
- Publication number
- WO1993012779A1 WO1993012779A1 PCT/GB1992/002347 GB9202347W WO9312779A1 WO 1993012779 A1 WO1993012779 A1 WO 1993012779A1 GB 9202347 W GB9202347 W GB 9202347W WO 9312779 A1 WO9312779 A1 WO 9312779A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- histamine
- receptor antagonist
- dose
- gastric
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the treatment of gastric disorders and pharmaceutical compositions for use therein. More particularly the invention relates to the local treatment of gastric disorders, especially acute gastric disorders such as acid indigestion, heartburn and gastritis, and gastric and peptic ulcer, using orally administrable pharmaceutical compositions comprising a histamine H_2-receptor antagonist contained within a drug delivery system. Compositions for use in the invention are specifically adapted to provide local delivery across the stomach wall to the H_2-receptor on the parietal cell receptor.
- Histamine H_2-receptor antagonists for example cimetidine, ranitidine, nizetidine and famotidine, reduce acid secretion by acting directly on the acid-secreting parietal cell located within the gastric gland of the stomach wall.
- histamine H2-receptor antagonists are remarkably effective in the treatment of many gastric disorders, in particular peptic and gastric ulcers, there exist certain patient groups which do not respond to treatment.
- the time lapse between dosing and onset of action limits the potential benefit of histamine H2-receptor antagonists in the treatment of acute, self-limiting gastric disorders.
- Histamine H2-receptor antagonists are of potential benefit in the self-medication of acute, self-limiting gastric disorders such as hyperacidity. However, their slow onset of action is unlikely to meet the consumer requirement for rapid relief of symptoms.
- histamine H2-receptor antagonists and other pharmaceutically active materials, including antacids, has been investigated.
- the rationale for co-administration with antacid is that the antacid brings about rapid relief from the symptoms of excess stomach acidity by neutralisation whereas the histamine H2-receptor antagonist acts independently by inhibiting secretion of acid from the parietal cell.
- histamine H2-receptor antagonists are co-administered with antacids, especially antacids with high acid-neutralising capacity, a substantial reduction in the plasma bioavailability of the histamine H2-receptor antagonist is frequently observed. Histamine H2-receptor antagonist - antacid combinations are therefore generally contraindicated.
- EP-A-0 193400 (Reckitt and Colman) describes pharmaceutical compositions comprising mixtures of a histamine H2-receptor antagonist and sodium polyacrylate in the weight ratio 10 : 1 to 1 : 10.
- the compositions are described for use in the treatment of gastritis or gastro- duodenal ulcers.
- the compositions may include an antacid. Use of antacid is described as resulting in a reduction in the viscosity of the liquid compositions, thereby providing some degree of viscosity control in the design of readily pourable liquid preparations.
- EP-A-0 193 400 discloses a normal unit dosage of histamine H2-receptor antagonist in the range 800 to lOmg in the case of cimetidine and in the range 150 to 5mg in the case of ranitidine.
- histamine H2 ⁇ receptor antagonists act systemically, i.e. the histamine H2-receptor antagonist is delivered to the parietal cell receptor from the blood.
- the increase in acid-secretion reducing capacity is described as being advantageous in the treatment of ulcer patients, in particular hypersecreting patients, in the treatment of those patients diagnosed as non-responders, and also to reduce the onset-phase of single-dose, self- medication for acute gastric disorders, for example gastric orders due to hyperacidity.
- WO 92/00102 discloses a dose level of the H2-receptor antagonist cimetidine from about 25 to 400mg, typically from about 50 to 200mg of cimetidine per dosage form. Dosage levels between 25 and 50mg of cimetidine are lower than those currently regarded as conferring therapeutic benefit.
- the potential for using reduced dose levels of histamine H2-receptor antagonist, brought about by synergy between the histamine H2-receptor antagonist and antacid, is described as an advantageous feature of local delivery.
- histamine H2- receptor antagonist and antacid is effective in increasing local stomach wall receptor site bioavailability of the histamine H2-receptor antagonist through local delivery to the parietal cell tissue receptor at very low dosage levels of the histamine H2-receptor antagonist so as to provide therapeutic benefit without reliance on synergy between histamine H2- receptor antagonist and polyacrylate.
- the present invention provides the use of an orally administrable pharmaceutical composition comprising a histamine H2-receptor antagonist and an antacid, for the manufacture of a medicament for the treatment of gastric disorders, whereby the composition is optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H2-receptor antagonist, characterised in that the dose of histamine H2-receptor antagonist per unit dosage form is less than 25mg.
- Histamine H2-receptor antagonists for use in compositions of the invention include cimetidine, ranitidine and famotidine, preferably cimetidine and ranitidine, and especially cimeditine.
- pKa values for known histamine H2 ⁇ receptor antagonists are readily available from pharmacological publications.
- the dose of histamine H2-receptor antagonist may be selected according to the potency of the chosen antagonist on a weight basis and according to the severity of the condition.
- a suitable dose of antagonist when cimetidine is between lmg and 25mg, preferably between lmg and lOmg, for example 5,10,15 or 20mg.
- a suitable dose of antagonist when ranitidine is between lmg and 25mg, preferably between lmg and lOmg, more preferably between lmg and 5mg, for example 1,2,3,4,5,10,15 or 20mg.
- the invention also provides a method of treatment of gastric disorders comprising administering to a sufferer an effective amount of a locally acting pharmaceutical composition comprising a histamine H2-receptor antagonist and an antacid, optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H2 ⁇ receptor antagonist, whereby the dose of histamine H2 ⁇ receptor antagonist per unit dosage form is less than ⁇ jmg.
- the invention provides a locally acting pharmaceutical composition for use in the treatment of gastric disorders which comprises a histamine H2 ⁇ receptor antagonist and an antacid, optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H2- receptor antagonist, whereby the dose of histamine H2-receptor antagonist per unit dosage form- is less than 2? ig.
- compositions for use in the invention are optimally buffered by the use of a buffering component which is suitably an antacid having equilibrium pH, acid neutralising, capacity and gastric residence time values which provide a pH profile with time conferring a local pH level substantially equal to that of the pKa of the histamine H2-receptor antagonist.
- a buffering component which is suitably an antacid having equilibrium pH, acid neutralising, capacity and gastric residence time values which provide a pH profile with time conferring a local pH level substantially equal to that of the pKa of the histamine H2-receptor antagonist.
- Suitable buffering agents for use in compositions of the invention include aluminium hydroxide, magnesium hydroxide, aluminium hydroxide-magnesium carbonate co-dried gel, magnesium carbonate, magnesium oxide, magnesium aluminium silicate, magnesium trisilicate, sodium bicarbonate, calcium carbonate, bismuth carbonate, alkali metal salts of citric, tartaric, benzoic, sorbic and phosphoric acid, and combinations thereof.
- antacids may be selected by pharmacokinetic analysis of the acid-secretion reducing capacity of a selected histamine H2-receptor antagonist using a pharmacokinetic model based upon a modified, standard two-compartment model.
- a pharmacokinetic model based upon a modified, standard two-compartment model.
- the model demonstrates the reduction in local bioavailability of the histamine H2-receptor antagonist at the parietal cell tissue receptor compartment as a function of gastric excretion and the increase in local bioavailability in the parietal cell tissue receptor compartment as a function of local, gastric absorption, and their dependence on gastric pH.
- Gastric pH levels are influenced by antacid.
- antacid By inserting known values for equilibrium pH, acid neutralising capacity and gastric residence time, the suitability of any given antacid may be determined.
- histamine H2-receptor antagonist therapies act systemically and drug is distributed to all parts of the body via the bloodstream. Hence, it will be appreciated that non-target body tissues are exposed to drug.
- An advantage of a locally targeted drug delivery system is that very low doses of the histamine H2-receptor antagonist may be used and thus pharmacologically relevant doses are not achieved in non-target tissues.
- Excretion of histamine H2-receptor antagonist into the stomach lumen from the parietal cell tissue receptor causes a reduction in local bioavailability of the antagonist whilst gastric absorption of histamine H2-receptor antagonist into the parietal cell tissue receptor causes an increase in local bioavailability of the antagonist.
- the advantageous feature of the invention of using reduced dose levels of histamine H2 ⁇ receptor antagonist is brought about by buffering the histamine H2-receptor antagonist in the gastric environment, effectively reducing antagonist excretion into the stomach lumen, increasing absorption from the stomach lumen, and increasing the residence time of the hist, ine H2-receptor antagonist in the gastric environment.
- treatment with the present compositions provides a more rapid onset of action which renders them particularly suitable for the treatment of acute gastritis.
- a further aspect of the invention is that the amount of antacid present in any given composition is independent of the dose of histamine H2-receptor antagonist.
- the level of antacid or buffering component is optimally chosen to confer a pH substantially equal to that of the pKa of the histamine H2-receptor antagonist.
- buffering component serves a dual role. In one aspect, in the accepted mode of action of antacids, it brings about relief from the symptoms of excess stomach acidity by neutralisation. In a second aspect, and more importantly, it serves to act as ah appropriate buffered vehicle to enhance the absorption of the histamine H2-receptor antagonist.
- the dose of buffering agent may be selected to achieve both effects.
- a suitable dose range for magnesium hydroxide is from about 150 mg to 3000 mg, for example from about 300 mg to 1500 mg, such as from about 300 mg to 600 mg.
- a suitable dose range for aluminium hydroxide is from about 180 mg to 3600 mg, for example from about 360 mg to 1800 mg, such as from 360 to 720 mg.
- a suitable dose range for sodium bicarbonate is from about 400mg to 8,000mg for example from about 800 mg to 4000mg, such as from about 800mg to 1600mg.
- compositions for use in the present invention may also contain pharmaceutically acceptable carriers.
- Compositions may be formulated for oral administration in solid or liquid form, for example as effervescent or non-effervescent powders or tablets, capsules, suspensions or dispersions.
- Compositions may thus be formulated by admixture with pharmaceutically acceptable vehicles additionally containing, as desired, pharmaceutically acceptable adjuvants including inter alia thickeners, preservatives, and colouring and flavouring agents.
- compositions for use in the present invention comprising very low doses of histamine H2-receptor antagonist are novel and as such form a further aspect of the invention.
- the ingredients are dry blended under conditions of controlled temperature and humidity using conventional equipment.
- the active antacid ingredients are granulated or spray dried in a conventional manner.
- the granule and the histamine H2-receptor antagonist are blended along with conventional tabletting aids, fillers and palatabflity aids and the blend is tabletted on a conventional machine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93900298A EP0617617A1 (en) | 1991-12-20 | 1992-12-17 | Compositions containing histamine-h2-receptor antagonists at low dosage |
AU31662/93A AU674501B2 (en) | 1991-12-20 | 1992-12-17 | Compositions containing histamine-H2-receptor antagonists at low dosage |
JP5511519A JPH07502527A (en) | 1991-12-20 | 1992-12-17 | Compositions containing low doses of histamine-H2-receptor antagonists |
US08/244,847 US5656652A (en) | 1991-12-20 | 1992-12-17 | Compositions containing histamine-H2 -receptor antagonists at low dosage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9127150.2 | 1991-12-20 | ||
GB919127150A GB9127150D0 (en) | 1991-12-20 | 1991-12-20 | Novel treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993012779A1 true WO1993012779A1 (en) | 1993-07-08 |
Family
ID=10706651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/002347 WO1993012779A1 (en) | 1991-12-20 | 1992-12-17 | Compositions containing histamine-h2-receptor antagonists at low dosage |
Country Status (7)
Country | Link |
---|---|
US (2) | US5656652A (en) |
EP (1) | EP0617617A1 (en) |
JP (1) | JPH07502527A (en) |
AU (1) | AU674501B2 (en) |
CA (1) | CA2126231A1 (en) |
GB (1) | GB9127150D0 (en) |
WO (1) | WO1993012779A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008997A1 (en) * | 1993-09-30 | 1995-04-06 | Glaxo Wellcome Inc. | Ranitidine and calcium carbonate pharmaceutical combination product |
WO1995016446A1 (en) * | 1993-12-16 | 1995-06-22 | Nippon Glaxo Limited | Ranitidine compositions |
WO1995027486A1 (en) * | 1994-04-12 | 1995-10-19 | Glaxo Group Limited | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion |
US5989588A (en) * | 1996-10-04 | 1999-11-23 | Merck & Co., Inc. | Methods and compositions for preventing and treating heartburn |
EP1019066A4 (en) * | 1996-10-04 | 2000-07-19 | Merck & Co Inc | Methods and compositions for preventing and treating heartburn |
WO2007090113A2 (en) | 2006-02-01 | 2007-08-09 | Weg Stuart L | Use of antifungal compositions to treat upper gastrointestinal conditions |
WO2017091166A1 (en) | 2015-11-26 | 2017-06-01 | Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. | Stable pharmaceutical compositions and process for their preparation |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000028988A1 (en) * | 1998-11-17 | 2000-05-25 | Nitromed, Inc. | Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
US6627234B1 (en) | 1998-12-15 | 2003-09-30 | Wm. Wrigley Jr. Company | Method of producing active agent coated chewing gum products |
US7163705B2 (en) * | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
US6586023B1 (en) | 1998-12-15 | 2003-07-01 | Wm. Wrigley Jr. Company | Process for controlling release of active agents from a chewing gum coating and product thereof |
US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
US6270807B1 (en) | 1999-03-02 | 2001-08-07 | L. Perrigo Company | Taste-masked pharmaceutical composition |
US6322806B1 (en) | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
JP2003509455A (en) * | 1999-04-06 | 2003-03-11 | ダブリューエム リグリー ジュニア カンパニー | Pharmaceutical chewing gum formulation |
US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US20020159956A1 (en) * | 1999-04-06 | 2002-10-31 | Ream Ronald L. | Over-coated chewing gum formulations |
US7935362B2 (en) | 1999-04-06 | 2011-05-03 | Wm. Wrigley Jr. Company | Over-coated product including consumable center and medicament |
US6355265B1 (en) | 1999-04-06 | 2002-03-12 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US6426090B1 (en) * | 1999-04-06 | 2002-07-30 | Wm. Wrigley Jr. Company | Over-coated product including tableted center and medicament |
US6541048B2 (en) | 1999-09-02 | 2003-04-01 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an acid blocker and process of preparing |
US6645535B2 (en) | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
US6569472B1 (en) | 2000-09-01 | 2003-05-27 | Wm. Wrigley Jr. Company | Coated chewing gum products containing antacid and method of making |
US6663849B1 (en) | 2000-09-01 | 2003-12-16 | Wm. Wrigley Jr. Company | Antacid chewing gum products coated with high viscosity materials |
US9253991B2 (en) | 1999-09-20 | 2016-02-09 | Jack Barreca | Chewing gum with B vitamins |
US9387168B2 (en) | 1999-09-20 | 2016-07-12 | Jack Barreca | Chewing gum with tomatidine |
AU3885201A (en) | 1999-09-20 | 2001-04-24 | Mastercare | Diet and weight control gum and sucker |
US6572900B1 (en) | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
US7115288B2 (en) * | 2000-06-09 | 2006-10-03 | Wm. Wrigley Jr. Company | Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener |
US6444241B1 (en) | 2000-08-30 | 2002-09-03 | Wm. Wrigley Jr. Company | Caffeine coated chewing gum product and process of making |
US6579545B2 (en) | 2000-12-22 | 2003-06-17 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an antigas agent |
US6663892B1 (en) | 2002-08-19 | 2003-12-16 | L. Perrigo Company | Multiple portion tablet |
DE102011083984A1 (en) * | 2011-10-04 | 2013-04-04 | Endress + Hauser Process Solutions Ag | Method for ensuring authorized access to a field device of automation technology |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193400A2 (en) * | 1985-03-01 | 1986-09-03 | Reckitt And Colman Products Limited | Pharmaceutical compositions |
EP0286781A2 (en) * | 1987-03-30 | 1988-10-19 | HEUMANN PHARMA GMBH & CO | Pharmaceutical preparation for treating gastro-intestinal tract diseases |
WO1992000102A1 (en) * | 1990-06-22 | 1992-01-09 | Beecham Group Plc | Novel treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2593065B1 (en) * | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | EFFERVESCENT COUPLES, EFFERVESCENT COMPOSITIONS OF HISTAMINE H2 ANTAGONISTS CONTAINING THEM AND THEIR PREPARATION. |
GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
IL85472A (en) * | 1987-03-09 | 1991-06-30 | Procter & Gamble | Pharmaceutical compositions for treating gastrointestinal disorders |
ATE81011T1 (en) * | 1987-03-09 | 1992-10-15 | Procter & Gamble | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS. |
GB8710965D0 (en) * | 1987-05-08 | 1987-06-10 | Smith Kline French Lab | Pharmaceutical compositions |
KR960011236B1 (en) * | 1987-05-08 | 1996-08-21 | 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 | Pharmaceutical compositions of cimetidine |
GB8730011D0 (en) * | 1987-12-23 | 1988-02-03 | Smithkline Dauelsberg | Pharmaceutical compositions |
US5275823A (en) * | 1989-04-27 | 1994-01-04 | Smith Kline & French Laboratories Ltd. | Pharmaceutical compositions |
GB9019875D0 (en) * | 1990-09-11 | 1990-10-24 | Glaxo Group Ltd | Pharmaceutical compositions |
-
1991
- 1991-12-20 GB GB919127150A patent/GB9127150D0/en active Pending
-
1992
- 1992-12-17 US US08/244,847 patent/US5656652A/en not_active Expired - Lifetime
- 1992-12-17 WO PCT/GB1992/002347 patent/WO1993012779A1/en not_active Application Discontinuation
- 1992-12-17 CA CA002126231A patent/CA2126231A1/en not_active Abandoned
- 1992-12-17 JP JP5511519A patent/JPH07502527A/en active Pending
- 1992-12-17 AU AU31662/93A patent/AU674501B2/en not_active Withdrawn - After Issue
- 1992-12-17 EP EP93900298A patent/EP0617617A1/en not_active Ceased
-
1995
- 1995-05-17 US US08/443,290 patent/US5629026A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193400A2 (en) * | 1985-03-01 | 1986-09-03 | Reckitt And Colman Products Limited | Pharmaceutical compositions |
EP0286781A2 (en) * | 1987-03-30 | 1988-10-19 | HEUMANN PHARMA GMBH & CO | Pharmaceutical preparation for treating gastro-intestinal tract diseases |
WO1992000102A1 (en) * | 1990-06-22 | 1992-01-09 | Beecham Group Plc | Novel treatment |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008997A1 (en) * | 1993-09-30 | 1995-04-06 | Glaxo Wellcome Inc. | Ranitidine and calcium carbonate pharmaceutical combination product |
AU677108B2 (en) * | 1993-09-30 | 1997-04-10 | Glaxo Wellcome Inc. | Ranitidine and calcium carbonate pharmaceutical combination product |
WO1995016446A1 (en) * | 1993-12-16 | 1995-06-22 | Nippon Glaxo Limited | Ranitidine compositions |
WO1995027486A1 (en) * | 1994-04-12 | 1995-10-19 | Glaxo Group Limited | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion |
US5989588A (en) * | 1996-10-04 | 1999-11-23 | Merck & Co., Inc. | Methods and compositions for preventing and treating heartburn |
EP1019066A4 (en) * | 1996-10-04 | 2000-07-19 | Merck & Co Inc | Methods and compositions for preventing and treating heartburn |
EP1019066A1 (en) * | 1996-10-04 | 2000-07-19 | Merck & Co., Inc. | Methods and compositions for preventing and treating heartburn |
WO2007090113A2 (en) | 2006-02-01 | 2007-08-09 | Weg Stuart L | Use of antifungal compositions to treat upper gastrointestinal conditions |
WO2017091166A1 (en) | 2015-11-26 | 2017-06-01 | Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. | Stable pharmaceutical compositions and process for their preparation |
Also Published As
Publication number | Publication date |
---|---|
US5629026A (en) | 1997-05-13 |
GB9127150D0 (en) | 1992-02-19 |
JPH07502527A (en) | 1995-03-16 |
EP0617617A1 (en) | 1994-10-05 |
CA2126231A1 (en) | 1993-07-08 |
AU674501B2 (en) | 1997-01-02 |
AU3166293A (en) | 1993-07-28 |
US5656652A (en) | 1997-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5629026A (en) | Compositions containing histamine-H2-receptor antagonists at low dosage | |
US5229137A (en) | Methods and pharmaceutical compositions for treating episodic heartburn | |
AU7981391A (en) | Novel treatment | |
AU659422B2 (en) | Composition containing antihistamine H2 receptor antagonists and bioadhesive material | |
WO1991015197A1 (en) | Pharmaceutical formulation | |
RU2126249C1 (en) | Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions | |
US4704278A (en) | Fluidized magaldrate suspension | |
AU4082793A (en) | Compositions based on histamine h2-receptor antagonists and cationic exchangers complexes | |
EP0492247A1 (en) | Effervescent H2 blocker formulation | |
NZ194165A (en) | Antacidaqueous suspension containing aluminium hydroxide | |
KR101153571B1 (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
Pace et al. | Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration. | |
Lai et al. | Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: report of two cases | |
AU2003204688B2 (en) | Liquid antacid compositions | |
AU730391B2 (en) | Liquid antacid compositions | |
KR960011773B1 (en) | Pharmaceutical compositions for the gastric ulcer prevention and therapy | |
AU677108B2 (en) | Ranitidine and calcium carbonate pharmaceutical combination product | |
EP1019066A1 (en) | Methods and compositions for preventing and treating heartburn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993900298 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08244847 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2126231 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1993900298 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1993900298 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993900298 Country of ref document: EP |